Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals (VRX): Bill Ackman’s Pershing Square Lands Board Seat

Page 1 of 7

Bill Ackman‘s Pershing Square has filed a Form 13D on Valeant Pharmaceuticals Intl Inc. (NYSE:VRX). The filing shows that Pershing Square owns 30.71 million shares of the beleaguered pharmaceutical company, unchanged from a filing issued by Ackman’s firm in early February. More importantly, the filing reveals that Valeant recently added three independent directors to its board, including Pershing Square’s Vice Chairman Stephen Fraidin.

Item 4 of the filing was updated with the following information:

On March 9, 2016, the Issuer announced that its board of directors (the Board) appointed Stephen Fraidin, Vice Chairman of Pershing Square, as well as Fred Eshelman and Thomas W. Ross, Jr., as independent directors, effective immediately.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Pershing Square Capital Management 0 30,711,122 0 30,711,122 30,711,122 9.0%
PS Management GP 0 30,711,122 0 30,711,122 30,711,122 9.0%
William A. Ackman 0 30,711,122 0 30,711,122 30,711,122 9.0%
Bill Ackman
Bill Ackman
Pershing Square

Page 1 of 7 SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

VALEANT
PHARMACEUTICALS INTERNATIONAL, INC.

(Name of Issuer)

Common Stock

(Title of
Class of Securities)

91911K102

(CUSIP Number)

Steve
Fraidin

Steve Milankov

Pershing Square Capital Management, L.P.

888 Seventh Avenue, 42nd Floor

New York, New York 10019

212-813-3700

With a
Copy to:

Richard M. Brand

Cadwalader, Wickersham & Taft LLP

One World Financial Center

New York, NY 10281

212-504-5757

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 8, 2016

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!
Page 1 of 7
Loading...